Microdosimetry for Targeted Alpha Therapy of Cancer

Targeted alpha therapy (TAT) has the advantage of delivering therapeutic doses to individual cancer cells while reducing the dose to normal tissues. TAT applications relate to hematologic malignancies and now extend to solid tumors. Results from several clinical trials have shown efficacy with limited toxicity. However, the dosimetry for the labeled alpha particle is challenging because of the heterogeneous antigen expression among cancer cells and the nature of short-range, high-LET alpha radiation. This paper demonstrates that it is inappropriate to investigate the therapeutic efficacy of TAT by macrodosimetry. The objective of this work is to review the microdosimetry of TAT as a function of the cell geometry, source-target configuration, cell sensitivity, and biological factors. A detailed knowledge of each of these parameters is required for accurate microdosimetric calculations.

[1]  D. Goodhead.  Panel discussion: Do non-targeted effects impact the relation between microdosimetry and risk? , 2011, Radiation Protection Dosimetry.

[2]  L. Pinsky,et al.  A database of frequency distributions of energy depositions in small-size targets by electrons and ions. , 2011, Radiation protection dosimetry.

[3]  Amin I Kassis,et al.  Therapeutic radionuclides: biophysical and radiobiologic principles. , 2008, Seminars in nuclear medicine.

[4]  C. Seidl.  Radioimmunotherapy with α-particle-emitting radionuclides. , 2014, Immunotherapy.

[5]  T. Karagiannis.  Comparison of different classes of radionuclides for potential use in radioimmunotherapy. , 2007, Hellenic journal of nuclear medicine.

[6]  Xuping Zhu,et al.  Solid-tumor radionuclide therapy dosimetry: New paradigms in view of tumor microenvironment and angiogenesis. , 2010, Medical physics.

[7]  S. Larson,et al.  Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia , 2010, Clinical Cancer Research.

[8]  A. Bosserhoff,et al.  Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma , 2007, Cancer biology & therapy.

[9]  B. Wessels,et al.  MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.

[10]  S. Kennel,et al.  Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi , 1999, British Journal of Cancer.

[11]  V. Rajkumar,et al.  Radioimmunotherapy: optimizing delivery to solid tumors. , 2011, Therapeutic delivery.

[12]  W. Roesch.  Microdosimetry of internal sources. , 1977, Radiation research.

[13]  T. Waldmann,et al.  Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Dudley T Goodhead,et al.  Energy deposition stochastics and track structure: what about the target? , 2006, Radiation protection dosimetry.

[15]  T. Stokke,et al.  Radioimmunotherapy with Alpha-Particle Emitters: Microdosimetry of Cells with a Heterogeneous Antigen Expression and with Various Diameters of Cells and Nuclei , 2001, Radiation research.

[16]  Stavroula Sofou.  Radionuclide carriers for targeting of cancer , 2008, International journal of nanomedicine.

[17]  G. Sgouros.  Alpha-particles for targeted therapy. , 2008, Advanced drug delivery reviews.

[18]  J. Humm,et al.  Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody , 2011, Physics in medicine and biology.

[19]  M. Zalutsky,et al.  Radioimmunotherapy with alpha-particle emitting radionuclides. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[20]  S. Adelstein,et al.  A Comparison of Experimental and Calculated Survival Curves for V79 Cells Grown as Monolayers or in Suspension Exposed to Alpha Irradiation from 212Bi Distributed in the Growth Medium , 1994 .

[21]  B. Allen.  Clinical trials of targeted alpha therapy for cancer. , 2008, Reviews on recent clinical trials.

[22]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[23]  Barry J. Allen,et al.  Simultaneous macro and micro dosimetry with MOSFETs , 1996 .

[24]  M. Pomper,et al.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy. , 2011, Medical physics.

[25]  Karin Schwab,et al.  Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  J C Roeske,et al.  Dosimetric framework for therapeutic alpha-particle emitters. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  M Bardiès,et al.  Evidence of Extranuclear Cell Sensitivity to Alpha-Particle Radiation Using a Microdosimetric Model. I. Presentation and Validation of a Microdosimetric Model , 2009, Radiation research.

[28]  P. Barberet,et al.  Monte Carlo dosimetry for targeted irradiation of individual cells using a microbeam facility. , 2009, Radiation protection dosimetry.

[29]  R. Macklis,et al.  Review of clinical radioimmunotherapy , 2006, Expert review of anticancer therapy.

[30]  C. Coleman,et al.  Radioimmunotherapy with alpha-particle-emitting immunoconjugates. , 1988, Science.

[31]  S. Fosså,et al.  First Clinical Experience with α-Emitting Radium-223 in the Treatment of Skeletal Metastases , 2005, Clinical Cancer Research.

[32]  J. Humm,et al.  A model of cell inactivation by alpha-particle internal emitters. , 1993, Radiation research.

[33]  G T Chen,et al.  Microdosimetric concepts in radioimmunotherapy. , 1993, Medical physics.

[34]  B. Allen.  Can α-radioimmunotherapy increase efficacy for the systemic control of cancer? , 2011, Immunotherapy.

[35]  J C Roeske,et al.  Analytic microdosimetry for radioimmunotherapeutic alpha emitters. , 1992, Medical physics.

[36]  B. Oborn,et al.  Background Dose for Systemic Targeted Alpha Therapy , 2011 .

[37]  P. Bradley,et al.  Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy. , 1998, Medical physics.

[38]  B. Oborn,et al.  Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. , 2012, Medical physics.

[39]  J. Roeske,et al.  Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. , 1999, Radiation research.

[40]  Habib Zaidi,et al.  Therapeutic Applications of Monte Carlo Calculations in Nuclear Medicine , 2002 .

[41]  D. Scheinberg,et al.  Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids , 2004, Clinical Cancer Research.

[42]  J. Humm,et al.  Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.

[43]  B. Allen,et al.  Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer , 2007, Physics in medicine and biology.

[44]  M Bardiès,et al.  Dosimetry and microdosimetry of targeted radiotherapy. , 2000, Current pharmaceutical design.

[45]  P. Moretto,et al.  A comparison of cellular irradiation techniques with alpha particles using the Geant4 Monte Carlo simulation toolkit. , 2006, Radiation protection dosimetry.

[46]  A B Rosenfeld,et al.  Performance of silicon microdosimetry detectors in boron neutron capture therapy. , 1999, Radiation research.

[47]  D. Scheinberg,et al.  Tumor Therapy with Targeted Atomic Nanogenerators , 2001, Science.